In our randomised , open-label , phase @ study , we recruited women ( aged @ years ) who had measurable platinum-sensitive , relapsed , high-grade serous or endometrioid ovarian , fallopian tube , or primary peritoneal cancer , or those with deleterious germline BRCA@/@ mutations from nine participating US academic medical centres .